Newman Dignan & Sheerar, Inc. Adaptimmune Therapeutics PLC Transaction History
Newman Dignan & Sheerar, Inc.
- $585 Million
- Q3 2024
A detailed history of Newman Dignan & Sheerar, Inc. transactions in Adaptimmune Therapeutics PLC stock. As of the latest transaction made, Newman Dignan & Sheerar, Inc. holds 27,957 shares of ADAP stock, worth $17,333. This represents 0.0% of its overall portfolio holdings.
Number of Shares
27,957Holding current value
$17,333% of portfolio
0.0%Shares
3 transactions
Others Institutions Holding ADAP
# of Institutions
83Shares Held
150MCall Options Held
60.8KPut Options Held
5.8K-
Matrix Capital Management Company, LP Waltham, MA37.7MShares$23.4 Million1.71% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA27.4MShares$17 Million1.13% of portfolio
-
Nea Management Company, LLC Timonium, MD17.1MShares$10.6 Million1.24% of portfolio
-
Baillie Gifford & CO16.8MShares$10.4 Million0.01% of portfolio
-
Long Focus Capital Management, LLC San Juan, PR13.3MShares$8.25 Million0.46% of portfolio
About Adaptimmune Therapeutics PLC
- Ticker ADAP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 163,370,000
- Market Cap $101M
- Description
- Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...